Feline Leukemia Virus, Kawakami-Theilen

Verify with FDA CVM →

109 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
109
Total Reports
15
Deaths Reported
1380.0%
Death Rate

Active Ingredients

Feline Leukemia Virus, Kawakami-Theilen

Administration Routes

Subcutaneous

Species Affected

Cat 109

Most Affected Breeds

Domestic Shorthair 71
Domestic Longhair 15
Domestic Mediumhair 7
Cat (other) 5
Siamese 3
Norwegian Forest 2
Selkirk Rex 1
Ragdoll 1
Snowshoe 1
Balinese 1

Most Reported Reactions

Fever 33
Lethargy (see also Central nervous system depression in 'Neurological') 31
Lethargy (see also Central nervous system depression in Neurological) 22
Vomiting 20
Anorexia 20
Not eating 18
Decreased appetite 13
Weight loss 13
Pain NOS 11
Lack of efficacy - NOS 11
Death by euthanasia 10
Hiding 9

Outcome Breakdown

Ongoing
60 (54.5%)
Recovered/Normal
27 (24.5%)
Euthanized
10 (9.1%)
Outcome Unknown
7 (6.4%)
Died
5 (4.5%)
Recovered with Sequela
1 (0.9%)

Data Summary

Metric Value
Total adverse event reports 109
Reports involving death 15
Case-fatality rate (reported events) 1380.0%
Distinct species in reports 1
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Feline Leukemia Virus, Kawakami-Theilen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 109 adverse event reports referencing Feline Leukemia Virus, Kawakami-Theilen, including 15 reports in which the animal died — a 1380.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Feline Leukemia Virus, Kawakami-Theilen. Reported administration route is Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Feline Leukemia Virus, Kawakami-Theilen reports are Cat (109 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (71), Domestic Longhair (15), Domestic Mediumhair (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Feline Leukemia Virus, Kawakami-Theilen are Fever (33), Lethargy (see also Central nervous system depression in 'Neurological') (31), Lethargy (see also Central nervous system depression in Neurological) (22), Vomiting (20). Of the 110 reports with a coded outcome, Ongoing is the leading category at 54.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Feline Leukemia Virus, Kawakami-Theilen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial